Myocardial ischemia & viability

Paolo G. Camici, Ornella Rimoldi

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The increasing use of thrombolytic therapy and primary percutaneous coronary interventions in association with optimized anti-thrombotic therapy has contributed to significantly reducing short-term mortality and morbidity in patients with acute coronary syndromes. The change of the epidemiology of myocardial infarction over the past 2 decades is due to the increase in NSTEMI infarctions counterbalanced by a substantial reduction in ST-segment elevation [1]. Nevertheless, no further improvement in long term survival could be observed, probably due to the greater number of patients with residual left ventricular (LV) dysfunction undergoing progressive LV remodeling and congestive heart failure (CHF). A problem compounded by the rising age of the population and the higher prevalence of co-morbidities such as diabetes mellitus and hypertension which confer an increased risk of coronary artery disease (CAD) and CHF. Patients with CAD represent by far the most numerous cohort amongst those with CHF and their treatment remains a partial success [2].

Original languageEnglish
Title of host publicationClinical Applications of Cardiac CT
PublisherSpringer-Verlag Italia s.r.l.
Pages59-67
Number of pages9
ISBN (Print)9788847025226, 8847025214, 9788847025219
DOIs
Publication statusPublished - Nov 1 2013

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'Myocardial ischemia & viability'. Together they form a unique fingerprint.

Cite this